entertainment -WSS

entertainment

author：explore 2025-09-27 22:46:57 - browse：6577

After physically debilitating cancer treatment, Laurie Brunner encountered another medical hurdle: She had developed lymphedema that required surgery, but her BMI was over the cutoff. To receive the necessary treatment, she would have to lose weight.

“But after everything I’ve been through, my body was just not having it,” she said. So she turned to Jody Dushay, an endocrinologist at the Beth Israel Deaconess Medical Center and assistant professor of medicine at Harvard Medical School. After much discussion, the two decided that Laurie should try using weight loss medication — specifically, Wegovy — so she could become eligible for the surgery.

Before long, they had to grapple with the shortage of GLP-1 medications. “Within the first two months she had a good response,” Jody said. But “then there was the first round of shortages. … It looks like, you know, we’re heading towards that finish line. And then, ‘Oh, sorry, you can’t get it anymore.’”

On the “First Opinion Podcast,” I spoke with Jody and Laurie about how the ongoing shortages of GLP-1 medications are creating logistical and medical problems. Our conversation was based on Jody’s recent First Opinion essay, “How the Wegovy shortage is making life impossible for my patients — and for me.” We talked about the patient and provider perspective, the way stigma affects access to care, the ways weight loss medications are changing the medical system, and how the drug shortage is only part of the problem of access.

Be sure to sign up for the weekly “First Opinion Podcast” on Apple Podcasts, Spotify, Google Play, or wherever you get your podcasts.

Previous article： Tori Bowie and the unacceptable rates of Black maternal death
Next article： Medicare solvency divides Republicans at the presidential debate

hotspot

WSS

UCSF medical school apologizes for unethical prisoner experiments

Study: New antibiotic targets gonorrhea as well as last existing drug

Readout Newsletter: Bristol, Sangamo, Gilead, and more

STAT Executive Editor Rick Berke on STAT's 8th birthday

More doctors should go into startup world

R.J. Reynolds sues to protect 'crisp' cigs from California flavor ban

knowledge

entertainment

entertainment

Medical records are filled with copy

Biotech incubator Curie.Bio graduates its first startup

Medicare details structure of new drug price negotiation program

UCLA team creates talking throat patch for voice disorders

Walensky prepares to leave CDC — and Congress — behind

Amid AI frenzy, a top HHS official's quest to create safeguards

FDA approval of Sarepta Duchenne genetic therapy gives me hope

Don't let 'shelved assets' gather dust. Make them into new lifesaving drugs

Cancer drug shortages should be causing more outrage

MoonLake credibility takes another hit with mid

leisure time

Acadia's Nuplazid fails as schizophrenia medicine in Phase 3 study

Study: New antibiotic targets gonorrhea as well as last existing drug

Why scientists need input from humanists on sensitive research

Change Healthcare outage fallout shows need for new oversight

Just how powerful is the placebo effect?

Sanofi CEO defends move to abandon profit guidance, boost research

hotspot

hotspot

focus

leisure time